**Subscribe** 

**Past Issues** 

#### View this email in your browser



CSE: AIML

OTCQB: AIMLF

FWB: 42FB

## The Pulse:

### The Latest from AI/ML Innovations Inc.

19/06/25

#### In Case You Missed It:

- AIML strengthens its IP portfolio with provisional patents for AI-driven ECG signal processing
- FDA's AI pilot sparks rapid rollout to speed up review processes
- Small waves, big implications: P wave analysis saves lives.
- ECG waveforms tell a complex story about your heart's health.

## **Latest Announcements**

**Subscribe** 

Past Issues



Read Full Press
Release

#### subsidiary, files provisional patents.

Groundbreaking AI-driven ECG signal processing advance clinical diagnostics capabilities. The patents cover advanced neural architectures implemented in the company's MaxYield™ and CardioYield™ platforms, featuring a dynamic ECG reporting engine that supports clinical workflows.

## **Industry Watch**

# FDA is set to fully integrate AI across all centers by June 2025

The FDA completed its first AI-assisted scientific review pilot, a significant milestone in their mission to streamline the review process. With a full agencywide AI integration planned by June 2025, this initiative promises to drastically reduce review times and enhance overall efficiency.



Read Full Article

**Subscribe** 

**Past Issues** 

### **Must-Reads & Featured Articles**



Read Full Article

P waves hold critical diagnostic value beyond standard ECG readings.

MaxYield enhances P wave detection and analysis. Represents atrial depolarization, the first electrical event in cardiac cycle. Early identification of P wave irregularities helps prevent serious cardiac complications

# ECG waveforms tell a complex story about your heart's health.

Explore how ECG morphology reveals critical cardiac information through distinct waveform patterns, how these morphologies indicate specific heart conditions, AI's growing role in ECG analysis, and the connection between genetic testing and ECG pattern heritability.



Read Full Article

Subscribe Past Issues

## About AI/ML Innovations Inc. (CSE:AIML|OTCQB:AIMLF|FWB:42FB)

AIML deploys advanced AI and neural-network signal-processing to turn noisy biometric data- starting with ECG - into diagnostic-grade insight. Our flagship MaxYield™ platform, now in FDA 510(k) review, powers wearables and remote-monitoring systems worldwide. With provisional patents filed for these innovations, we're setting the stage for next-gen ECG technologies. As we continue to expand our IP portfolio and refine our solutions, AIML remains committed to advancing healthcare with precision and speed, empowering better cardiac care worldwide.

#### Learn More







Copyright (C) 2025 AI/ML Innovations Inc.. All rights reserved.

Our mailing address is:

Want to change how you receive these emails?

You can <u>update your preferences</u> or <u>unsubscribe</u>